Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study

• Published in: Nutrition (Burbank, Los Angeles County, Calif.) Vol. 114; p. 112090
• Main Authors: Guarneiri, Liana L., Wilcox, Meredith L., Maki, Kevin C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2023; Elsevier Limited
• Subjects: Absorption; Alcohol; Bioavailability; Blood pressure; Data collection; DHA; Diet; Dietary supplements; Dosage; Double-blind studies; Drug dosages; EPA; Fatty acids; Fish oil; Fish oils; Krill; Krill oil; Nutrition research; Phospholipids; Plasma levels; Seafood; Skin cancer; Urine; Womens health; United States > US; Krill oil; Phospholipids; DHA; Fish oil; EPA
• DOI: 10.1016/j.nut.2023.112090
• ISSN: 0899-9007; 1873-1244

•Absorption of EPA+DHA from a phospholipid-enhanced fish oil (PEFO) product vs. a krill oil product was similar over 24 hours.•The absorption profiles between the two products differed (higher and earlier peak for PEFO).•Both products were well accepted and tolerated and presented no safety concerns. This randomized, double-blind, crossover study evaluated the bioavailability of eicosapentaenoic and docosahexaenoic acids (EPA+DHA) in a phospholipid-enhanced fish oil (PEFO) product versus a krill oil (KO) product (337 versus 206 mg EPA+DHA/1 g capsule) in healthy adults (N = 24). The aim of this study was to assess the plasma levels of EPA, DHA, and EPA+DHA following a single capsule of PEFO versus KO products in healthy adult men and women. Participants consumed a single dose of the assigned product, and plasma was obtained at baseline and periodically for 24 h after dosing. The geometric mean ratio (GMR; 90% confidence interval) of incremental areas under the curve over 24 h PEFO:KO was 319/385 = 0.83 (0.60, 1.15 nmol/L*h), indicating a similar average increment for EPA+DHA with PEFO compared with KO across the 24-h period. The baseline-adjusted maximum concentration of EPA+DHA was greater for PEFO than KO (GMR: 1.25; 90% CI, 1.03–1.51). Finally, the geometric mean for the time to maximum concentration for EPA+DHA was lower for PEFO versus KO (P < 0.05). Absorption of EPA+DHA from the two products was similar, but the absorption profiles differed (higher and earlier peak for PEFO).